Showing 1 - 20 results of 29 for search 'A. N. Uskov', query time: 0.02s Refine Results
  1. 1
    Chronic course of Ixodes tick borreliosis in Krasnoyarsk region

    Chronic course of Ixodes tick borreliosis in Krasnoyarsk region by N. S. Minoranskaya, A. N. Uskov, E. I. Minoranskaya

    Published 2014-09-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Importance of immune status for prognosis chronic borreliosis infections

    Importance of immune status for prognosis chronic borreliosis infections by N. S. Minoranskaya, A. N. Uskov, P. V. Sarap

    Published 2014-09-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Clinical case of Ixodes-borne borreliosis an erythema form in combination with oncologic disease

    Clinical case of Ixodes-borne borreliosis an erythema form in combination with oncologic disease by A. N. Uskov, V. F. Krumgoltz, M. V. Yaremenko

    Published 2014-09-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    95 years of protecting and improving the health of children (devoted to the 95th anniversary of Pediatric Research and Clinical Center for Infectious Diseases)

    95 years of protecting and improving the health of children (devoted to the 95th anniversary of Pediatric Research and Clinical Center for Infectious Diseases) by N. V. Skripchenko, A. N. Uskov, V. M. Volzhanin

    Published 2022-04-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia

    Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia by A. V. Rudakova, A. N. Uskov, S. M. Kharit, S. V. Sidorenko

    Published 2014-09-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Assessment of reduction of rotavirus infection burden in case of vaccination with a pentavalent vaccine in Russian Federation

    Assessment of reduction of rotavirus infection burden in case of vaccination with a pentavalent vaccine in Russian Federation by A. V. Rudakova, S. M. Kharit, A. N. Uskov, Yu. V. Lobzin

    Published 2014-09-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1)

    Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1) by A. V. Rudakova, D. A. Gusev, A. N. Uskov, Yu. V. Lobzin

    Published 2016-02-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Antiviral therapy in chronic hepatitis C (G1) in Russia: cost and effectiveness

    Antiviral therapy in chronic hepatitis C (G1) in Russia: cost and effectiveness by A. V. Rudakova, D. A. Gusev, A. N. Uskov, Yu. V. Lobzin

    Published 2015-04-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Cost-effectiveness of quadrivalent human papillomavirus vaccination in adolescent girls

    Cost-effectiveness of quadrivalent human papillomavirus vaccination in adolescent girls by A. V. Rudakova, S. M. Kharit, A. S. Lisianskaya, A. N. Uskov, Yu. V. Lobzin

    Published 2016-11-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Clinical experience with ursodeoxycholic acid (Urdoxa) in complex therapy of chronic viral hepatitis

    Clinical experience with ursodeoxycholic acid (Urdoxa) in complex therapy of chronic viral hepatitis by E. V. Esaulenko, O. E. Nikitina, N. V. Dunaeva, A. N. Uskov, T. L. Mogilevets

    Published 2014-09-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines

    The averted costs due to influenza vaccination with trivalent and quadrivalent vaccines by S. M. Kharit, A. M. Rudakova, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin

    Published 2017-06-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers

    Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers by D. A. Gusev, A. V. Rudakova, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin

    Published 2016-11-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    COST-EFFECTIVENESS OF ANTIVIRAL THERAPY IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C (GENOTYPE 1) WITH VARIOUS SEVERITY OF FIBROSIS STAGE

    COST-EFFECTIVENESS OF ANTIVIRAL THERAPY IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C (GENOTYPE 1) WITH VARIOUS SEVERITY OF FIBROSIS STAGE by A. V. Rudakova, D. A. Gusev, A. N. Uskov, I. V. Shestakova, Yu. V. Lobzin

    Published 2018-01-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION

    PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION by A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin

    Published 2017-04-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Сost-effectiveness of the second wave of protease inhibitors in the treatment of chronic hepatitis C (genotype 1) in patients not previously treated with antiviral drugs, and for relapsed disease

    Сost-effectiveness of the second wave of protease inhibitors in the treatment of chronic hepatitis C (genotype 1) in patients not previously treated with antiviral drugs, and for r... by A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin

    Published 2016-04-01
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    THE EFFICACY OF THE COSTS ON SEVERE RESPIRATORY SYNCYTIAL INFECTION PREVENTION WITH PALIVIZUMAB IN PRETERM INFANTS

    THE EFFICACY OF THE COSTS ON SEVERE RESPIRATORY SYNCYTIAL INFECTION PREVENTION WITH PALIVIZUMAB IN PRETERM INFANTS by A. V. Rudakova, I. V. Babachenko, V. B. Rovnyi, A. N. Uskov, Yu. V. Lobzin

    Published 2012-07-01
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Cost-effectiveness of antiviral therapy in treatment-naive patients with chronic hepatitis C (genotype 1)

    Cost-effectiveness of antiviral therapy in treatment-naive patients with chronic hepatitis C (genotype 1) by A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin

    Published 2017-06-01
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    EFFECTIVENESS OF GELATIN TANNATE IN ACUTE INFECTIOUS DIARRHEA IN CHILDREN

    EFFECTIVENESS OF GELATIN TANNATE IN ACUTE INFECTIOUS DIARRHEA IN CHILDREN by M. K. Bekhtereva, A. M. Komarova, A. N. Uskov, I. V. Razdyakonov, L. A. Alekseeva, T. V. Bessonova

    Published 2017-12-01
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    MOLECULAR-GENETIC MECHANISMS OF PLASMODIUM FALCIPARUM VIRULENCE AND TROPICAL MALARIA PATHOGENESIS

    MOLECULAR-GENETIC MECHANISMS OF PLASMODIUM FALCIPARUM VIRULENCE AND TROPICAL MALARIA PATHOGENESIS by A. N. Uskov, A. I. Soloviev, V. Yu. Kravtsov, R. V. Gudkov, E. V. Kolomoets, A. E. Levkovskiy

    Published 2018-10-01
    Get full text
    Article
    Save to List
    Saved in:
  20. 20
    Cost effectiveness analysis of universal varicella vaccination in the Russian Federation

    Cost effectiveness analysis of universal varicella vaccination in the Russian Federation by A. V. Rudakova, S. M. Kharit, I. V. Babachenko, L. N. Konovalova, S. V. Rychkova, A. N. Uskov, Yu. V. Lobzin

    Published 2021-10-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: